Published in Mol Pharmacol on September 01, 2003
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis (2005) 1.29
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer (2010) 1.25
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs (2005) 1.09
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J (2009) 1.08
Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis (2008) 1.05
Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J Med Res (2014) 0.96
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Front Pharmacol (2010) 0.93
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer (2010) 0.93
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol (2007) 0.90
CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res (2009) 0.90
Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms. Mol Endocrinol (2011) 0.88
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol (2010) 0.88
PharmGKB summary: caffeine pathway. Pharmacogenet Genomics (2012) 0.86
Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol (2003) 0.85
Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol (2005) 0.84
Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls. Eur J Clin Pharmacol (2006) 0.84
Pharmacogenetics of analgesic drugs. Br J Pain (2013) 0.83
CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med (2010) 0.82
Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. Eur J Clin Pharmacol (2005) 0.81
CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial. Cancer Epidemiol Biomarkers Prev (2009) 0.81
High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS (2013) 0.81
PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics (2012) 0.80
Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay. J Autism Dev Disord (2015) 0.79
CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. BMC Cancer (2016) 0.76
The Impact of CYP1A2 and CYP2E1 Genes Polymorphism on Theophylline Response. J Clin Diagn Res (2016) 0.75
In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect (2017) 0.75
Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis. PLoS One (2017) 0.75
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr (2004) 3.01
Pharmacogenomics and individualized drug therapy. Annu Rev Med (2006) 2.95
Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit (2004) 2.84
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics (2006) 1.80
Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis (2002) 1.73
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol (2010) 1.71
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos (2013) 1.59
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics (2008) 1.52
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics (2010) 1.44
GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area. Nutr Cancer (2010) 1.42
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet (2011) 1.42
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis (2012) 1.41
Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol Sci (2010) 1.26
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol (2011) 1.24
The importance of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic liver disease in rats. Gastroenterology (2002) 1.24
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol (2008) 1.22
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos (2003) 1.20
Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med (2008) 1.20
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun (2005) 1.19
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One (2011) 1.17
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun (2005) 1.15
Effect of Achyranthes aspera L. on fetal abortion, uterine and pituitary weights, serum lipids and hormones. Afr Health Sci (2006) 1.14
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol (2006) 1.13
CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer (2003) 1.13
Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol (2007) 1.11
Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers (2002) 1.11
Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci (2010) 1.11
Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos (2009) 1.10
The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther (2003) 1.09
Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics (2014) 1.09
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol (2008) 1.08
Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol (2007) 1.08
Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med (2005) 1.08
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol (2003) 1.08
Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. Cell Signal (2005) 1.07
Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp Biol Med (Maywood) (2008) 1.06
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics (2006) 1.06
Heterozygous loss-of-function variants in CYP1B1 predispose to primary open-angle glaucoma. Invest Ophthalmol Vis Sci (2009) 1.05
Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. J Biotechnol (2009) 1.05
The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol (2008) 1.04
Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol Pharmacol (2004) 1.04
Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control (2003) 1.04
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother (2011) 1.04
Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol (2013) 1.04
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol (2003) 1.03
Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One (2008) 1.03
β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans. J Infect Dis (2012) 1.03
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics (2006) 1.02
Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci (2011) 1.02
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun (2006) 1.02
Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol (2005) 1.01
3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol Sci (2013) 1.01
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol (2008) 1.01
Phytochemical screening and pharmacological evaluations for the antifertility effect of the methanolic root extract of Rumex steudelii. J Ethnopharmacol (2005) 1.01
Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int (2013) 1.00
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. Hum Mutat (2008) 1.00
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J (2009) 1.00
Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol (2010) 0.98
Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. Glia (2007) 0.98
Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat (2002) 0.97
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol (2002) 0.97
Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis (2003) 0.97
CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics (2005) 0.97
Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics (2007) 0.96
Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis (2003) 0.96
Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. Mol Pharmacol (2010) 0.96
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet (2009) 0.95
Antifertility effect of aqueous and ethanol extracts of the leaves and roots of Asparagus africanus in rats. Afr Health Sci (2006) 0.94
The possible mechanisms for the antifertility action of methanolic root extract of Rumex steudelii. Afr Health Sci (2005) 0.94
DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie (2012) 0.94
Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study. Mutat Res (2005) 0.94
Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria. J Biol Chem (2011) 0.94
In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. Nucleic Acids Res (2013) 0.94
MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol (2009) 0.93
Intracellular transport and localization of microsomal cytochrome P450. Anal Bioanal Chem (2008) 0.93
Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet (2010) 0.92
CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study. BMC Cancer (2010) 0.92
Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern Lab Anim (2006) 0.91
Databases in the area of pharmacogenetics. Hum Mutat (2011) 0.91
CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol (2008) 0.91
Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. Methods Mol Biol (2013) 0.91
Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet Genomics (2009) 0.91
Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. Biochem Biophys Res Commun (2005) 0.91
CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev (2008) 0.91
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol (2010) 0.91
IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. Biochem Pharmacol (2010) 0.90
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol (2007) 0.90
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol (2003) 0.90